L-arginine as a therapeutic approach for the verotoxigenic Escherichia coli-induced hemolytic uremic syndrome and thrombotic thrombocytopenic purpura

Medical Hypotheses

Volumn 49, Issue 3, 1997, Pages 277-280

  Jaradat, Z W ^a   Marquardt, R R ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; NITRIC OXIDE; PROSTACYCLIN; VEROTOXIN;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; DISEASE SEVERITY; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; HYPERTENSION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOTAL PARENTERAL NUTRITION; TOXIN SYNTHESIS; VASODILATATION;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; PURPURA;

EID: 0030614313     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-9877(97)90213-9     Document Type: Article

References (35)

1. Lingwood C A. Verotoxin-binding in human renal sections. Nephron 1994; 66: 21-28.
2. Cleary T G. Cytotoxin-producing Escherichia coli and hemolytic uremic syndrome. Pediatr Clin North Am 1988; 35: 485-501.
3. Zoja C, Corna D, Farina C et al. Verotoxin glycolipid receptors determine the localization of microangiopathic process in rabbits given verotoxin-1. J Lab Clin Med 1992; 120: 229-238.
4. Gyles C L. Escherichia coli verotoxins and other cytotoxins. In: Gyles C L, ed. Escherichia coli in Domestic Animals and Humans. Wallingford: CAB International 1994: 365-398.
5. Karmali M A. Infection by verotoxin-producing Escherichia coli. Clin Microbiol Rev 1989; 2: 15-38.
6. Ostroff S M, Kobayashi J M, Lewis J H. Infections with Escherichia coli O157:H7 in Washington State. J Am Med Assoc 1989; 262: 355-359.
7. Padhye N V, Doyle M P. Escherichia coli O157:H7: epidemiology, pathogenesis, and methods for detection in food. J Food Prot 1992; 55: 555-565.
8. Takeda T, Dohi S, Yamanaka T, Yoshiya K, Kobayashi N. Impairment by verotoxin of tubular function contributes to the renal damage seen in hemolytic uremic syndrome. J Infect 1993; 27: 339-431.
9. Doyle M P. Escherichia coli O157:H7 and its significance in foods. Int J Food Microbiol 1991; 12: 289-302.
10. Kwaan H C. Clinicopathologic features of thrombotic thrombocytopenic purpura. Sem Hematol 1987; 24: 71-81.
11. Konowalchuk J, Speirs J L, Stavric S. Vero response to cytotoxin of Escherichia coli. Infect Immun 1977; 18: 775-779.
12. O'Brien A D, Holmes R K. Shiga and shiga like toxins. Microbiol Rev 1987; 51: 206-220.
13. Gyles C L. Escherichia coli. In: Gyles C L, Thoem C O, eds. Pathogenesis of Bacterial Infections in Animals. Ames, Iowa: Iowa State University Press, 1993: 164-187.
14. Kittell F B, Padhye V V, Doyle M P. Characterisation and inactivation of verotoxin 1 produced Escherichia coli O157:H7. J Agr Food Chem 1991; 39: 141-145.
15. Neill M A. E. coli O157:H7 - current concepts and future prospects. J Food Saf 1989; 10: 99-106.
16. Endo Y, Tsurug K, Yutsudo T, Tadeda Y, Ogasawara T, Igarashi K. Site of action of a vero toxin (VT2) from Escherichia coli O157:H7 and of shiga toxin on eukaryotic ribosomes. Eur J Biochem 1987; 87: 45-50.
17. Gyles C L. Escherichia coli cytotoxins and enterotoxins. Can J Microbiol 1992; 38: 734-746.
18. Schiffrin E L. The endothelium and control of blood vessel function in health and disease. Clin Invest Med 1994; 17: 602-620.
19. Lian E C Y, Savaraj N. Effects of platelet inhibitors on the platelet aggregation induced by plasma from patients with thrombotic thrombocytopenic purpura. Blood 1981; 58: 354-359.
20. Osborne J A, Lento P H, Siegfried M R, Stahl G L, Fusman B, Lefer A M. Cardiovascular effects of acute hypercholesterolemia in rabbits. J Clin Invest 1989; 83: 465-473.
21. Service R F. E. coli scare spawns therapy search. Science 1994; 265: 475.
22. Cimolai N, Carter J E. Epidemiology of the hemolytic uremic syndrome. N Engl J Med 1991; 234: 1065-1066.
23. Cimolai N, Carter J E, Morrison B J, Andersen J D. Risk factors from the progression of E. coli O157:H7 enteritis to hemolytic uremie syndrome. J Pediatr 1990; 116: 589-592.
24. Machin S J. Clinical annotation. Br J Hematol 1984; 56: 191-197.
25. Rose P E, Armour J A, Williams C E, Hill F. Verotoxin and neuraminidase induced platelet aggregating activity in plasma: their possible role in the pathogenesis of the hemolytic uremic syndrome. J Clin Pathol 1985; 38: 438-441.
26. Marletta M A. Nitric oxide: biosynthesis and biological significance. Trends Biomed Sci 1989; 14: 488-492.
27. Conger J D, Robinette J B, Schrier R W. Smooth muscle calcium and endothelium-derived relaxing factor in the abnormal vascular responses of acute renal failure. J Clin Invest 1988; 82: 532-537.
28. Lincoln T M, Cornwell T L. Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels 1991; 28: 129-137.
29. Beckman J S, Beckman T W, Chen J, Marshall P A, Freeman B A. Apparent hydroxyl radical production by peroxynitraite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-1624.
30. Lefer A M, Liefer D J. The L-arginine-nitric oxide pathway as a key regulatory mechanism in cell-to-cell communication. Biomol Res News 1993; 4: 1-3.
31. Radomski M W, Palmer R M J, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-187.
32. Bulgrin J P, Shabani M, Smith D J. Arginine-free diet suppresses nitric oxide production in wounds. J Nutr Biochem 1993; 4: 588-593.
33. Reyes A A, Karl I E, Klahr S. Role of arginine in health and in renal disease. Am J Physiol 1994; 267: F331-F346.
34. Salazar F J, Alberola A, Nakamura T, Granger J P. Role of nitric oxide in the renal hemodynamic response to a meat meal. Am J Physiol 1994; 267: R1050-R1055.
35. Barbul A, Lazarou S A, Efron D T, Wasserkrug H L, Efron G. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 1990; 108: 331-337.